Sihuan Pharma Passes Inspection for New GI Drug

Sihuan Pharma passed an SFDA on-site inspection for a first-to-market injected generic drug, Roxatidine, a gastrointestinal product. Sihuan expects marketing approval from the SFDA within three months, allowing the company to launch the drug in the second half of the year. For Sihuan, which has traditionally been known as a cardio-cerebral vascular company, Roxatidine represents an expansion of the company’s traditional franchise. More details.... Stock Symbol: (HK: 0460) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});